Organovo Holdings, Inc,
Organovo Holdings, Inc, is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Organovo Holdings, Inc,.
Organovo Holdings, Inc, is a company.
Key people at Organovo Holdings, Inc,.
Key people at Organovo Holdings, Inc,.
Organovo Holdings, Inc. (ONVO) is a clinical-stage biotechnology company specializing in 3D bioprinting technology to create functional human tissues that mimic native tissue architecture, function, and disease characteristics for drug discovery and development.[1][2][3][4][5] The company builds 3D human tissue models, particularly for inflammatory bowel disease (IBD) like ulcerative colitis and Crohn’s disease, serving pharmaceutical researchers and developers by solving the problem of inaccurate preclinical drug testing through more predictive *in vitro* models that improve clinical trial success rates.[3][5][6] Its lead product, FXR314—an oral FXR agonist—targets ulcerative colitis (with FDA Phase 2 authorization) and potential expansions to Crohn’s, NASH, and Primary Biliary Cholangitis; growth includes a recent rebrand to VivoSim Labs (ticker VIVS) after a 1-for-12 reverse stock split in March 2025, though revenue remains low at $0.1 million in 2024 with 13 employees.[3][7]
Founded in 2007 and headquartered in San Diego, California, Organovo emerged as a pioneer in 3D bioprinting, using its proprietary NovoGen MMX Bioprinter to develop functional human tissues for medical research.[3][6] The idea stemmed from advancing drug discovery by bridging gaps in traditional 2D models, with early traction from partnerships like a 2015 deal with L'Oréal for 3D printed skin testing and collaborations with biopharma and academic centers.[6] Key milestones include going public via OTC reverse merger in 2012 (uplisting to NYSE MKT in 2013, peaking at $700M market cap), developing FXR314 with preclinical success, and a pivotal February 2025 asset sale of its FXR program to Eli Lilly for $10M, followed by the transition to VivoSim Labs.[3][6][7]
Organovo rides the 3D bioprinting and organ-on-a-chip trend in biotech, addressing failures in traditional drug testing (90%+ attrition rates) by providing human-relevant models that cut costs and speed development.[3][5][6] Timing aligns with rising demand for precise, ethical alternatives amid AI-driven drug discovery and precision medicine; market forces like FDA support for advanced models and pharma's push for de-risked pipelines favor it.[5] The company influences the ecosystem through tech licensing (e.g., to Eli Lilly), partnerships with biopharma/academia, and contributions to cosmetics/pharma testing, potentially reshaping regenerative therapies.[4][6][7]
Organovo (now VivoSim Labs) will prioritize advancing its 3D platform post-FXR sale, focusing on IBD/liver therapies and new tissue models amid Nasdaq compliance efforts.[3][7] Trends like AI integration in bioprinting, expanded FDA validations, and biotech M&A could accelerate growth, evolving its role from early innovator to key enabler in human-centric drug discovery. With low revenue but validated tech, strategic pivots like the rebrand signal resilience, positioning it to capture value in a market projected to boom as 3D tissues become standard for de-risking pipelines—echoing its founding promise to transform preclinical testing.[5][6][7]
